1. Advances in Coronary Artery Disease: Moving Beyond Antiplatelet Therapy

3. Program Goals

4. Antiplatelet Therapy for CAD: Established Therapy

5. Anticoagulant Therapy for CAD Warfarin -- WARIS-2

6. Anticoagulant Therapy With NOACs for CAD Apixaban -- APPRAISE-2

7. Rivaroxaban: ATLAS ACS 2—TIMI 51

8. ATLAS ACS 2—TIMI 51 Primary Efficacy Outcome

9. ATLAS ACS 2—TIMI 51 Bleeding Outcome

10. Dabigatran: RE-DEEM Primary and Secondary Outcome

11. ATLAS ACS 2—TIMI 51 Mortality and Stent Thrombosis

12. NOACs Plus Antiplatelet Agents: Lessons Learned

13. WOEST Dual vs Triple Therapy

14. WOEST Primary and Secondary Outcome

15. PIONEER AF-PCI Trial Design

16. PIONEER AF-PCI Clinically Significant Bleeding

17. PIONEER AF-PCI Substudy First Recurrent Hospitalization Due to Bleeding

18. Ongoing NOAC Trials in Patients With AF-PCI

19. COMPASS Trial Design

20. COMPASS Trial Design (cont)

21. COMPASS Inclusion/Exclusion Criteria

22. Targets of Antithrombotic Agents

23. COMPASS MIND

24. Concluding Remarks

25. Abbreviations

26. Abbreviations (cont)